{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:41:13Z","timestamp":1784299273665,"version":"3.55.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to evaluate the analytical and clinical performance of the Abbott Alinity TRAb chemiluminescent microparticle immunoassay and establish the reference interval for healthy Chinese populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The precision, analytical sensitivity and linearity of Abbott TRAb assay were verified in accordance with the Clinical and Laboratory Standards Institute guidelines. A total of 300 samples from patients with Grave\u2019s disease (GD) and other thyroid diseases were collected for method comparison and clinical performance verification. The performance of Abbott and Snibe TRAb assays was compared to Roche TRAb assay by correlation and agreement analysis. The diagnostic performance of Abbott TRAb assay was analyzed via receiver operating characteristic (ROC) analysis. The reference interval of Abbott TRAb was established from a cohort of 366 healthy individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Abbott Alinity TRAb assay demonstrated excellent precision, with repeatability (CV%) ranging from 1.04% to 5.92%, and within-laboratory imprecision (CV%) ranging from 1.09% to 5.92%. Manufacturer-claimed limits of blank, detection, and quantification were successfully verified. Linearity was confirmed from 1.14 to 47.72 IU\/L. Strong correlation was observed between Abbott and Roche assays (Spearman r\u2009=\u20090.972; slope\u2009=\u20091.060), while Snibe and Roche assays showed lower correlation (r\u2009=\u20090.784). Concordance analysis showed the total agreement with Roche results were 97.7% for Abbott and 96.7% for Snibe. Diagnostic accuracy of the Abbott TRAb assay for GD was high, yielding an area under curve (AUC) of 0.999, sensitivity of 98.4%, and specificity of 99.4% at an optimal cutoff of 2.89 IU\/L. The upper reference limits at 95\n                      <jats:sup>th<\/jats:sup>\n                      percentile and 97.5\n                      <jats:sup>th<\/jats:sup>\n                      percentile for healthy Chinese population using Abbott TRAb assay were 1.56 IU\/L and 1.95 IU\/L, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated the robustness of Abbott Alinity TRAb CMIA in clinical use with its verified analytical and clinical performance and established the reference interval for Chinese population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0339494","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:31:06Z","timestamp":1770229866000},"page":"e0339494","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Performance evaluation and reference interval establishment of Abbott Alinity thyroid-stimulating hormone receptor antibody (TRAb) assay for diagnosing Graves\u2019 disease"],"prefix":"10.1371","volume":"21","author":[{"given":"Hao","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jize","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-9702","authenticated-orcid":true,"given":"Yong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"6","key":"pone.0339494.ref001","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ando.2018.09.002","article-title":"Graves\u2019 disease: Introduction, epidemiology, endogenous and environmental pathogenic factors","volume":"79","author":"J-L W\u00e9meau","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"pone.0339494.ref002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"PN Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"pone.0339494.ref003","doi-asserted-by":"crossref","first-page":"101387","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves\u2019 disease: Epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"A Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"pone.0339494.ref004","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12020-017-1306-5","article-title":"Epidemiology, management and outcomes of Graves\u2019 disease-real life data","volume":"56","author":"YS Hussain","year":"2017","journal-title":"Endocrine"},{"issue":"16","key":"pone.0339494.ref005","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"TJ Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"pone.0339494.ref006","doi-asserted-by":"crossref","first-page":"651534","DOI":"10.3389\/fendo.2021.651534","article-title":"Hyperthyroidism prevalence in china after universal salt iodization","volume":"12","author":"C Wang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0339494.ref007","doi-asserted-by":"crossref","first-page":"525936","DOI":"10.1155\/2012\/525936","article-title":"The role of thyrotrophin receptor antibody assays in graves\u2019 disease","volume":"2012","author":"C Kamath","year":"2012","journal-title":"J Thyroid Res"},{"issue":"5","key":"pone.0339494.ref008","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrendo.2013.56","article-title":"GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis","volume":"9","author":"MJ Simmonds","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"pone.0339494.ref009","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001052","article-title":"Thyrotropin receptor antibodies-an overview","volume":"34","author":"A Kotwal","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"pone.0339494.ref010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12020-020-02386-2","article-title":"Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti\u2011TSHR immunoassay for Graves\u2019 disease: a Chinese multicenter study","volume":"71","author":"X Cheng","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"pone.0339494.ref011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.autrev.2012.07.003","article-title":"TSH receptor autoantibody immunoassay in patients with Graves\u2019 disease: improvement of diagnostic accuracy over different generations of methods. systematic review and meta-analysis","volume":"12","author":"R Tozzoli","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"12","key":"pone.0339494.ref012","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22468","article-title":"Comparison of two different TSH-receptor antibody assays: a clinical practice study","volume":"9","author":"M van Balkum","year":"2023","journal-title":"Heliyon"},{"issue":"8","key":"pone.0339494.ref013","article-title":"Evaluation of the diagnostic performance of thyroid-stimulating immunoglobulin and thyrotropin receptor antibodies for Graves\u2019 disease","volume":"37","author":"S Xu","year":"2023","journal-title":"J Clin Lab Anal"},{"issue":"2","key":"pone.0339494.ref014","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/cen.13908","article-title":"Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves\u2019 disease","volume":"90","author":"P Nalla","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"pone.0339494.ref015","doi-asserted-by":"crossref","DOI":"10.20945\/2359-3997000000609","article-title":"Prediction for recurrence following antithyroid drug therapy for Graves\u2019 hyperthyroidism","volume":"67","author":"H Weng","year":"2023","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"pone.0339494.ref016","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3892\/etm.2016.3058","article-title":"Predicting relapse of Graves\u2019 disease following treatment with antithyroid drugs","volume":"11","author":"L Liu","year":"2016","journal-title":"Exp Ther Med"},{"issue":"1","key":"pone.0339494.ref017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3343\/alm.2019.39.1.3","article-title":"Laboratory testing in thyroid conditions - pitfalls and clinical utility","volume":"39","author":"SB Soh","year":"2019","journal-title":"Ann Lab Med"},{"key":"pone.0339494.ref018","doi-asserted-by":"crossref","first-page":"1463379","DOI":"10.3389\/fendo.2024.1463379","article-title":"A novel bioassay for thyroid-blocking immunoglobulins","volume":"15","author":"A George","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"pone.0339494.ref019","doi-asserted-by":"crossref","first-page":"101744","DOI":"10.1016\/j.beem.2023.101744","article-title":"Bioassays for thyrotropin receptor autoantibodies","volume":"37","author":"PD Olivo","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"16","key":"pone.0339494.ref020","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/diagnostics13162707","article-title":"Evaluation of the Abbott Alinity i thyroid-stimulating hormone receptor antibody (TRAb) chemiluminescent microparticle immunoassay (CMIA)","volume":"13","author":"DJW Lee","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"9378","key":"pone.0339494.ref021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(03)13866-4","article-title":"Human monoclonal thyroid stimulating autoantibody","volume":"362","author":"J Sanders","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"pone.0339494.ref022","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1089\/1050725042451248","article-title":"A new assay for thyrotropin receptor autoantibodies","volume":"14","author":"BR Smith","year":"2004","journal-title":"Thyroid"},{"issue":"10","key":"pone.0339494.ref023","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/thy.2007.0239","article-title":"TSH receptor antibodies","volume":"17","author":"BR Smith","year":"2007","journal-title":"Thyroid"},{"issue":"1","key":"pone.0339494.ref024","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13317-017-0097-2","article-title":"Chemiluminescent immunoassay technology: what does it change in autoantibody detection?","volume":"8","author":"L Cinquanta","year":"2017","journal-title":"Auto Immun Highlights"},{"issue":"7","key":"pone.0339494.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270890","article-title":"Anti-TSH receptor antibodies (TRAb): Comparison of two third generation automated immunoassays broadly used in clinical laboratories and results interpretation","volume":"17","author":"JM L\u00f3pez Ortega","year":"2022","journal-title":"PLoS One"},{"issue":"8","key":"pone.0339494.ref026","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1515\/cclm-2023-0181","article-title":"Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay","volume":"61","author":"L Pighi","year":"2023","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"pone.0339494.ref027","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2023-0026","article-title":"Analytical performance of Abbott\u2019s ARCHITECT and Alinity TSH-receptor antibody (TRAb) assays","volume":"61","author":"H Choksi","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"pone.0339494.ref028","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clinbiochem.2020.08.007","article-title":"Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays","volume":"86","author":"V Higgins","year":"2020","journal-title":"Clin Biochem"},{"issue":"12","key":"pone.0339494.ref029","article-title":"Evaluation of analytic and clinical performance of two immunoassays for detecting thyroid-stimulating receptor antibody in the diagnosis of Graves\u2019 disease","volume":"35","author":"Y Hu","year":"2021","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"pone.0339494.ref030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/bmm-2022-0666","article-title":"Establishment and analytical performance of light-initiated chemiluminescence assay method for detecting thyrotropin receptor antibody","volume":"17","author":"Y Sun","year":"2023","journal-title":"Biomark Med"},{"issue":"8","key":"pone.0339494.ref031","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1128\/CVI.00112-10","article-title":"Resampling approach for determination of the method for reference interval calculation in clinical laboratory practice","volume":"17","author":"IY Pavlov","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"15","key":"pone.0339494.ref032","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.clinbiochem.2012.06.022","article-title":"Establishment of reference intervals of 24 chemistries in apparently healthy adult Han population of Northern China","volume":"45","author":"S Yang","year":"2012","journal-title":"Clin Biochem"},{"issue":"19","key":"pone.0339494.ref033","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.21037\/atm-21-4031","article-title":"Establishment of the reference intervals of lymphocyte subsets for healthy Chinese Han adults and its influencing factors","volume":"9","author":"K Xu","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"pone.0339494.ref034","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3343\/alm.2021.41.1.77","article-title":"Reference intervals for thyroid-associated hormones and the prevalence of thyroid diseases in the Chinese population","volume":"41","author":"Y Zou","year":"2021","journal-title":"Ann Lab Med"},{"issue":"5","key":"pone.0339494.ref035","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/cen.12371","article-title":"Reference ranges of serum TSH, FT4 and thyroid autoantibodies in the Thai population: the national health examination survey","volume":"80","author":"C Sriphrapradang","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"pone.0339494.ref036","first-page":"154","article-title":"Reference Intervals of Thyrotropin, Thyroid Hormones, and Thyroid Autoantibodies in Adult and Older Individuals According to Iodine Status","volume":"36","author":"S Tanticharoenkarn","year":"2025","journal-title":"EJIFCC"},{"key":"pone.0339494.ref037","author":"CLSI","year":"2017"},{"key":"pone.0339494.ref038","author":"CLSI","year":"2017"},{"key":"pone.0339494.ref039","author":"CLSI","year":"2003"},{"key":"pone.0339494.ref040","year":"2020"},{"key":"pone.0339494.ref041","year":"2021"},{"key":"pone.0339494.ref042"},{"key":"pone.0339494.ref043","author":"CLSI","year":"2018"},{"key":"pone.0339494.ref044","author":"CLSI","year":"2016"},{"issue":"12","key":"pone.0339494.ref045","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1055\/s-0030-1267171","article-title":"Continuously increasing sensitivity over three generations of TSH receptor autoantibody assays","volume":"42","author":"K Z\u00f6phel","year":"2010","journal-title":"Horm Metab Res"},{"issue":"7","key":"pone.0339494.ref046","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/00365513.2017.1354257","article-title":"Comparison of three competitive immunoassays for measurement of TSH receptor antibodies in patients with Graves\u2019 disease","volume":"77","author":"S Doroudian","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"issue":"4","key":"pone.0339494.ref047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/a-1373-5523","article-title":"Predicting the relapse of hyperthyroidism in treated graves\u2019 disease with orbitopathy by serial measurements of TSH-receptor autoantibodies","volume":"53","author":"M St\u00f6hr","year":"2021","journal-title":"Horm Metab Res"},{"issue":"1","key":"pone.0339494.ref048","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5603\/EP.a2020.0062","article-title":"The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves\u2019 hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves\u2019 hyperthyroidism","volume":"72","author":"SS Zuhur","year":"2021","journal-title":"Endokrynol Pol"},{"issue":"7","key":"pone.0339494.ref049","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1515\/cclm-2022-0162","article-title":"TSH-receptor autoantibodies in patients with chronic thyroiditis and hypothyroidism","volume":"60","author":"M Giannone","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"pone.0339494.ref050","first-page":"105","article-title":"Interferences in immunoassay","volume":"25","author":"J Tate","year":"2004","journal-title":"Clin Biochem Rev"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:31:25Z","timestamp":1770229885000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339494"}},"subtitle":[],"editor":[{"given":"Ant\u00f3nio","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0339494","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}